MAIA Biotechnology Advances Phase 3 Trial for Telomere-Targeting Cancer Drug
Event summary
- MAIA Biotechnology presented the methodology and study design for its pivotal Phase 3 clinical trial (THIO-104) at the 2026 ASCO Annual Meeting on May 31, 2026.
- The trial evaluates ateganosine, a telomere-targeting agent, in third-line non-small cell lung cancer (NSCLC) patients resistant to checkpoint inhibitors and chemotherapy.
- First patient dosed in THIO-104 in December 2025, with screening and enrollment underway in Europe and Asia.
- ASCO 2026 poster presented by Tomasz Jankowski, M.D., Phase 2 THIO-101 lead investigator for Poland.
The big picture
MAIA Biotechnology's presentation at ASCO 2026 highlights the growing interest in telomere-targeting therapies for cancer. The Phase 3 trial of ateganosine represents a strategic shift towards overcoming resistance mechanisms in NSCLC, a significant unmet need in oncology. The success of this trial could validate a novel approach to cancer treatment, potentially expanding MAIA's market opportunities in the immunotherapy space.
What we're watching
- Trial Execution
- The pace at which MAIA can enroll patients in the THIO-104 trial will determine the timeline for potential regulatory approval.
- Clinical Efficacy
- Whether ateganosine can demonstrate superior overall survival compared to standard chemotherapy in third-line NSCLC patients.
- Market Potential
- How the success of ateganosine could position MAIA in the competitive landscape of immunotherapy for NSCLC.
Related topics